CLINICAL TRIALS

We are dedicated to developing innovative microbial therapies that have the potential to significantly improve the health and well-being of the patients we serve. To meet this goal, we conduct clinical trials to determine the safety and efficacy of the new therapies we develop.

ACTIVE TRIALS

Currently, the following Finch-sponsored trials are enrolling participants:

PRISM 3: A CLINICAL trial FOR RECURRENT C. Difficile Infection

PRISM 3 is a Phase 2 clinical trial evaluating the safety and effectiveness of using CP101, a Full-Spectrum Microbiota™ oral therapy, compared to a placebo, to prevent recurrence of Clostridium difficile infection (CDI). PRISM 3 is currently enrolling patients at clinical sites throughout the U.S.

To determine if you may be eligible for the trial, or to get more information please visit the PRISM 3 website or https://clinicaltrials.gov/ct2/show/NCT03110133